Cargando…

Prognostic Value of sST2 in Heart Failure

In recent years, there has been growing interest in the risk stratification for heart failure, and the use of multiple biomarkers to identify different pathophysiological processes associated with this condition. One such biomarker is soluble suppression of tumorigenicity-2 (sST2), which has shown s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sciatti, Edoardo, Merlo, Anna, Scangiuzzi, Claudio, Limonta, Raul, Gori, Mauro, D’Elia, Emilia, Aimo, Alberto, Vergaro, Giuseppe, Emdin, Michele, Senni, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299183/ https://www.ncbi.nlm.nih.gov/pubmed/37373664 http://dx.doi.org/10.3390/jcm12123970

Ejemplares similares

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
por: Sciatti, Edoardo, et al.
Publicado: (2022)

Heart failure therapy: the fifth card
por: Balestrieri, Giulio, et al.
Publicado: (2023)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Clinical application of personalized medicine: heart failure with preserved left ventricular ejection fraction
por: Gori, Mauro, et al.
Publicado: (2020)

Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

In pursuit of balance: renin–angiotensin–aldosterone system inhibitors and hyperkalaemia treatment
por: Sciatti, Edoardo, et al.
Publicado: (2023)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations
por: Iacovoni, Attilio, et al.
Publicado: (2019)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone
por: Aleksova, Aneta, et al.
Publicado: (2019)

Red cell distribution width (RDW) is correlated to time of oxygen desaturation < 90% and length of sleep apneas in patients with sleep disorder breathing (SDB) and acute heart failure with preserved ejection fraction (HFpEF)
por: Stamerra, Cosimo A., et al.
Publicado: (2023)

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2019)

Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies
por: Aimo, Alberto, et al.
Publicado: (2022)

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2020)

Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart
por: D’Elia, Emilia, et al.
Publicado: (2020)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Value of the HFA‐PEFF and H(2)FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study
por: Nicol, Martin, et al.
Publicado: (2023)

Circulating levels and prognostic cut‐offs of sST2, hs‐cTnT, and NT‐proBNP in women vs. men with chronic heart failure
por: Vergaro, Giuseppe, et al.
Publicado: (2022)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
por: Morfino, Paolo, et al.
Publicado: (2022)

Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis
por: Emdin, Michele, et al.
Publicado: (2023)

sST2 and Heart Failure—Clinical Utility and Prognosis
por: Dudek, Magdalena, et al.
Publicado: (2023)

An Intriguing Case Report of Functional Mitral Regurgitation Treated With MitraClip
por: Duino, Vincenzo, et al.
Publicado: (2015)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Current and emerging drug targets in heart failure treatment
por: Ghionzoli, Nicolò, et al.
Publicado: (2021)

An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug
por: D’Elia, Emilia, et al.
Publicado: (2021)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure
por: Binas, David, et al.
Publicado: (2018)

Building medical knowledge from real world registries: The case of heart failure
por: Aimo, Alberto, et al.
Publicado: (2018)

Rituximab as a novel treatment for heart failure: evidence from a case series
por: Aimo, Alberto, et al.
Publicado: (2019)

Intracoronary Delivery of Mitochondria to Prevent Ischemia–Reperfusion Injury: Challenging Pathway From Bench to Bedside
por: Aimo, Alberto, et al.
Publicado: (2020)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021)

Short-Term Prognosis Value of sST2 for an Unfavorable Outcome in Hypertensive Patients
por: Farcaş, Anca Daniela, et al.
Publicado: (2020)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Early sST2 Liberation after Implantation of a Left Ventricular Assist Device in Patients with Advanced Heart Failure
por: Opfermann, Philipp, et al.
Publicado: (2020)

Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions
por: Pan, Wei, et al.
Publicado: (2020)

Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure
por: Firouzabadi, Negar, et al.
Publicado: (2020)

Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis
por: Zhang, Tianyi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nq526c94s8m7jnk9vk6piao5f6